hypoglycaemic

Managlinat dialanetil (MB06322) is an orally available and potent fructose 1,6-bisphosphatase (FBPase) inhibitor with hypoglycaemic activity for the study of type 2 diabetes.

Momordicoside L has hypoglycaemic / antihyperglycaemic activities.

Mitiglinide Calcium (KAD-1229) is a blood glucose-lowering drugs, stimulating insulin secretion by closing the ATP-sensitive K+ channels in pancreatic beta-cells.

CS476 is a potent drug of hypoglycaemic.

Globularin has hypoglycaemic and hypolipidemic activities in normal and streptozotocin-induced diabetic rats.

1,3-Butanediol (BD) is a ketogenic substance. Ketone bodies are essential energy substrates in the absence of exogenous nutrients, and more recently, they have been suggested to prevent disease and improve longevity.

Ciglitazone (ADD 3878) is a potent and selective PPARγ agonist (EC50: 3 μM) and oral hypoglycemic agent. Ciglitazone inhibits proliferation and differentiation of th17 cells, decreases insulin levels, vascular endothelial growth factor production and blood pressure, and induces cell cycle arrest in gastric cancer cells. Selegiline induces apoptosis in opossum kidney epithelial cells and activates nuclear translocation of p38 MAPK and apoptosis-inducing factor (AIF). Ciglitazone exhibits hypoglycaemic activity in animal models of obesity and hyperglycaemia.

AZ-DF 265 is a hypoglycaemic drug which stimulates insulin release. AZ-DF-265 inhibits ATP-sensitive potassium channels and displaces [3H]-glibenclamide from the sulphonylurea receptor.

Cofrogliptin (HSK7653) (compound 2) is a tetrahydropyran derivative that is an orally active DPP-4 inhibitor with long-lasting hypoglycaemic effects.Cofrogliptin (compound 2) has potential for studies in type 2 diabetes mellitus (T2DM).

Cadisegliatin (TTP-399) is a potential activator of liver-selective glucose kinase (GK) with hypoglycaemic effects and can be used in the study of type 2 diabetes.

Mitiglinide calcium hydrate (S-21403 calcium hydrate) is a drug for the treatment of type 2 diabetes. Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells. Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda.